Last10K.com

X4 Pharmaceuticals, Inc (XFOR) SEC Filing 8-K Material Event for the period ending Wednesday, February 9, 2022

X4 Pharmaceuticals, Inc

CIK: 1501697 Ticker: XFOR

View differences made from one to another to evaluate X4 Pharmaceuticals, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by X4 Pharmaceuticals, Inc.

Continue

Assess how X4 Pharmaceuticals, Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

X4 Pharmaceuticals, Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

X4 Pharmaceuticals, Inc provided additional information to their SEC Filing as exhibits

Ticker: XFOR
CIK: 1501697
Form Type: 8-K Corporate News
Accession Number: 0001628280-22-002106
Submitted to the SEC: Wed Feb 09 2022 4:10:57 PM EST
Accepted by the SEC: Wed Feb 09 2022
Period: Wednesday, February 9, 2022
Industry: Biological Products No Disgnostic Substances
Events:
  1. New Agreement
  2. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/xfor/0001628280-22-002106.htm